bevacizumab
Bevacizumab is a drug used to treat Colorectal Cancer, Breast Cancer, Ovarian Cancer, and other conditions. Bevacizumab is being actively studied in 302 studies and prior, has been studied in 697.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
National Cancer Institute (NCI) | Dana-Farber Cancer Institute | DuNan |
Hoffmann-La Roche | Washington University School of Medicine | Peter C. Enzinger, MD |
M.D. Anderson Cancer Center | Massachusetts General Hospital | Vassilis Georgoulias, MD |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
- Chicago, IllinoisNorthwestern University
2022-03-10
Mar 10, 2022M
Recruiting
- BRAF V600 Wild Type
- +6 more
- Atezolizumab
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-03-01
Mar 1, 2022M
Active, not recruiting
- Invasive Breast Carcinoma
- Triple-Negative Breast Carcinoma
- Bevacizumab
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-02-18
Feb 18, 2022M
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +5 more
- Bevacizumab
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-02-24
Feb 24, 2022N
Recruiting
- Advanced Papillary Renal Cell Carcinoma
- +6 more
- Atezolizumab
- +2 more
- Bethesda, MarylandNational Cancer Institute LAO
2021-10-15
Oct 15, 2021N
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Bevacizumab
- +2 more
- Los Angeles, California
- +17 more
2022-01-25
Jan 25, 2022N
Recruiting
- Metastatic Colorectal Carcinoma
- +4 more
- Bevacizumab
- +4 more
- Columbus, OhioOhio State University Comprehensive Cancer Center
2021-12-14
Dec 14, 2021N
Recruiting
- Combined Hepatocellular Carcinoma and Cholangiocarcinoma
- +4 more
- Atezolizumab
- +3 more
- Danville, Illinois
- +5 more
2022-03-30
Mar 30, 2022N
Active, not recruiting
- Adult Glioblastoma
- +23 more
- Bevacizumab
- +3 more
- Boston, Massachusetts
- +2 more
2021-11-17
Nov 17, 2021C
Recruiting
- Locally Advanced Lung Non-Small Cell Carcinoma
- +9 more
- Bevacizumab
- Brigatinib
- Duarte, California
- +3 more
2021-11-15
Nov 15, 2021A
Active, not recruiting
- Metastatic Colorectal Carcinoma
- +5 more
- Atezolizumab
- +4 more
- Phoenix, Arizona
- +9 more
2022-01-05
Jan 5, 2022M
Active, not recruiting
- Appendix Adenocarcinoma
- +20 more
- Atezolizumab
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-02-25
Feb 25, 2022K
Not yet recruiting
- Carcinoma, Ovarian Epithelial
- pembrolizumab
- +5 more
- (no location specified)
2021-12-09
Dec 9, 2021A
Completed
- Colorectal Adenocarcinoma
- +4 more
- Bevacizumab
- +4 more
- Scottsdale, Arizona
- +12 more
2022-01-27
Jan 27, 2022M
Recruiting
- Cervical Adenocarcinoma
- +47 more
- Bevacizumab
- +3 more
- Phoenix, Arizona
- +3 more
2022-01-07
Jan 7, 2022N
Active, not recruiting
- Fallopian Tube Endometrioid Adenocarcinoma
- +7 more
- Anetumab Ravtansine
- +2 more
- Orange, California
- +22 more
2022-04-05
Apr 5, 2022N
Active, not recruiting
- Recurrent Glioblastoma
- Bevacizumab
- +3 more
- La Jolla, California
- +26 more
2022-03-25
Mar 25, 2022N
Recruiting
- Peritoneal Malignant Mesothelioma
- Atezolizumab
- +5 more
- Chicago, Illinois
- +8 more
2022-03-15
Mar 15, 2022T
Recruiting
- Ovarian Cancer
- Bevacizumab
- +2 more
- Tai'an, Shandong, ChinaThe Second Affiliated Hospital of Shandong First Medical Univers
2021-12-24
Dec 24, 2021S
Recruiting
- Brain Injuries
- Bevacizumab
- Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital
2022-03-20
Mar 20, 2022S
Recruiting
- Colorectal Cancer
- FOLFOX regimen
- +3 more
- Madrid, SpainSpanish Cooperative Group for the Treatment of Digestive Tumors
2022-03-08
Mar 8, 2022D
Active, not recruiting
- Glioblastoma
- Pembrolizumab
- +2 more
- Boston, Massachusetts
- +4 more
2022-03-14
Mar 14, 2022N
Recruiting
- Metastatic Alveolar Soft Part Sarcoma
- Unresectable Alveolar Soft Part Sarcoma
- Atezolizumab
- Bevacizumab
- Phoenix, Arizona
- +42 more
2022-02-08
Feb 8, 2022A
Recruiting
- Advanced Colorectal Carcinoma
- +15 more
- Bevacizumab
- +6 more
- Columbus, OhioOhio State University Comprehensive Cancer Center
2021-11-08
Nov 8, 2021G
Recruiting
- Glioblastoma Multiforme
- Bevacizumab
- Philadelphia, Pennsylvania(unnamed)
2022-03-14
Mar 14, 2022